PAMS
TPTX

Pictet Asset Management (Switzerland)’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-58,673
Closed -$4.42M – 1634
2022
Q2 		$4.42M Sell
58,673
-1,549,387
-96% -$68.9M 0.01% 786
2022
Q1 		$43.2M Sell
1,608,060
-70,833
-4% -$2.38M 0.05% 342
2021
Q4 		$80.1M Buy
1,678,893
+497,071
+42% +$22.2M 0.08% 260
2021
Q3 		$78.5M Buy
+1,181,822
New +$84.2M 0.09% 262

Pictet Asset Management (Switzerland)'s TPTX Position: Q3 2022 in Review

Pictet Asset Management (Switzerland) sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 58,673 shares — an estimated $4.42M sold.

Pictet Asset Management (Switzerland) first reported a position in TPTX in Q3 2021 and held it in 4 quarters. The position peaked at $80.1M in Q4 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Pictet Asset Management (Switzerland) reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Pictet Asset Management (Switzerland) sold 58,673 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $4.42M.
  • Pictet Asset Management (Switzerland) first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
  • Pictet Asset Management (Switzerland)'s Turning Point Therapeutics, Inc. Common Stock position peaked at $80.1M in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q3 2022, filed 14 Nov 2022.